Methylene Blue
Code | Size | Price |
---|
TAR-T6888-50mg | 50mg | £95.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6888-100mg | 100mg | £104.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6888-1mL | 1 mL * 10 mM (in DMSO) | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6888-200mg | 200mg | £114.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6888-500mg | 500mg | £132.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Methylene Blue(IC50 of 1.9 μM) inhibits tau filament formation. And it inhibits soluble guanylyl cyclase. It is also used as a dye in chromoendoscopy.
CAS:
61-73-4
Formula:
C16H18ClN3S
Molecular Weight:
319.85
Pathway:
GPCR/G Protein; Immunology/Inflammation; Cytoskeletal Signaling; Microbiology/Virology; Neuroscience
Purity:
0.97
SMILES:
[Cl-].CN(C)c1ccc2nc3ccc(cc3sc2c1)=[N+](C)C
Target:
Guanylate cyclase; Microtubule Associated; NO Synthase; Parasite; Monoamine Oxidase
References
Fan Z, Tian Y, Chen Z, et al. Blocking interaction between SHP2 and PD?1 denotes a novel opportunity for developing PD?1 inhibitors[J]. EMBO Molecular Medicine. 2020: e11571.
Vutskits L, et al. Anesthesiology. 108(4):684-692.
Ginimuge PR, et al. J Anaesthesiol Clin Pharmacol. 2010, 26(4):517-520.
Masaki E, et al. Anesth Analg. 1999, 89(2):484-489.
Fan Z, Tian Y, Chen Z, et al. Blocking interaction between SHP2 and PD?1 denotes a novel opportunity for developing PD?1 inhibitors. EMBO Molecular Medicine. 2020: e11571
Hochgr?fe K, et al. Acta Neuropathol Commun. 2015 May 10;3:25.